SCHEMBL24067374

SCHEMBL24067374

CCc1nc(C(C)(C)C)c2ccc(Cc3nc(C(C)(C)C)c4cc(OC)c(OC)cc4n3)cc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTSR1 P30989 3/20 0.42
PDE4A P27815 3/20 0.38
PDE4D Q08499 3/20 0.38
PDE10A Q9Y233 5/20 0.37
KDM4E B2RXH2 3/20 0.37
POLB P06746 1/20 0.37
LMNA P02545 5/20 0.37
SMN1; SMN2 Q16637 5/20 0.36
PDE3B Q13370 3/20 0.36
PDE3A Q14432 3/20 0.36
MAPK1 P28482 3/20 0.36
USP2 O75604 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP3A4 P08684 2/20 0.36
HIF1A Q16665 2/20 0.36
PDE2A O00408 1/20 0.36
ABCC4 O15439 1/20 0.36
PDE5A O76074 1/20 0.36
ABCB11 O95342 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24067384 0.87 NTSR1 (0.47) NTSR1PDE4APDE4DKDM4EPOLB
SCHEMBL24067370 0.77 ALDH1A1 (0.40) PDE4APDE4DKDM4EPOLBLMNA
SCHEMBL25670600 0.72 LMNA (0.35) KDM4ELMNAALDH1A1CYP1A2ACHE
SCHEMBL25844467 0.70
SCHEMBL25680896 0.69 NTSR1 (0.50) NTSR1PDE4APDE4DKDM4EPOLB
SCHEMBL25671167 0.69 PDE4A (0.51) PDE4APDE4DKDM4EPOLBLMNA
SCHEMBL24015771 0.69 NTSR1 (0.50) NTSR1PDE4APDE4DKDM4ESMN1; SMN2
SCHEMBL25670599 0.69 KDM4E (0.32) KDM4ESMN1; SMN2RAB9AMAPTHPGD
SCHEMBL14090663 0.68 SMN1; SMN2 (0.51) KDM4EPOLBSMN1; SMN2PDE3BPDE3A
SCHEMBL20813450 0.68 NTSR1 (0.49) NTSR1PDE4APDE4DKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701371-B2 ENPP1 inhibitors and their use for the treatment of cancer THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-07-18 US disclosed
US-20210369747-A1 ENPP1 Inhibitors and Their Use for the Treatment of Cancer THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2021-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701371-B2 ENPP1 inhibitors and their use for the treatment of cancer ENPP1, ENPP3, ENTPD1 NTSR1 3545/4885PDE4A 508/4885PDE4D 895/4885
US-20210369747-A1 ENPP1 Inhibitors and Their Use for the Treatment of Cancer ENPP1, ENPP3, ENTPD1 NTSR1 3545/4885PDE4A 508/4885PDE4D 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.